Clinical Report: Once-Daily Eye Drop for IOP Enters FDA Review
Overview
The FDA has accepted Kowa Pharmaceuticals' NDA for K-911, an investigational once-daily eye drop aimed at lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The NDA is supported by pivotal Phase III trials demonstrating noninferiority to latanoprost.
Background
Intraocular pressure (IOP) management is critical in slowing the progression of glaucoma, a leading cause of blindness. K-911, a nitric oxide-donating bimatoprost, aims to enhance IOP reduction through dual outflow pathways.
Data Highlights
No numerical data available in the source material.
Key Findings
K-911 is designed to lower IOP through two pathways: conventional and uveoscleral outflow.
The FDA has set a target action date of April 30, 2027, for the NDA review.
The NDA is supported by two Phase III trials, Mont Blanc and Denali, comparing K-911 to latanoprost.
K-911 remains investigational and has not yet received FDA approval.
Clinical Implications
K-911 remains investigational and has not yet received FDA approval.
Conclusion
K-911 remains investigational and has not yet received FDA approval.
